KT 2962

Drug Profile

KT 2962

Alternative Names: KT2 962

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kotobuki Seiyaku
  • Class Antiplatelets; Small molecules
  • Mechanism of Action Free radical scavengers; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Cerebrovascular disorders; Coronary thrombosis; Migraine; Reperfusion injury; Thrombosis

Most Recent Events

  • 02 Nov 2005 No development reported - Preclinical for Reperfusion injury in Japan (unspecified route)
  • 01 Apr 2003 Preclinical trials in Reperfusion injury in Japan (unspecified route)
  • 02 Oct 1997 Phase-I clinical trials for Asthma in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top